Abstracts Archive - Page 1334 of 2607 - ACR Meeting Abstracts

Abstract Number: 2216 • 2018 ACR/ARHP Annual Meeting
Detection of Left Ventricular Regional Function in Primary Sjögren’s Syndrome Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
Atsuma Nishiwaki¹, Natsumi Ikumi², Hitomi Kobayashi^3,4, Yasuyuki Kobayashi⁵, Isamu Yokoe⁴, Yosuke Nagasawa⁶, Kaita Sugiyama⁶, Takamasa Nozaki⁶, Mitsuhiro Iwata⁴, Noboru Kitamura⁴ and Masami Takei⁴, ¹Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Advanced Biomedical Imaging Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ⁶Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: The risk of major cardiovascular (CV) events and the long-term CV outcome in patients with primary Sjögren’s syndrome (pSS) remain unclear. Myocardial disease is…
Abstract Number: 2217 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Early Onset Gout in Outpatient Setting
Yan Li¹, Paramarajan Piranavan¹, Devi Sundaresan² and Robert A. Yood³, ¹Internal Medicine, St. Vincent Hospital, Worcester, MA, ²Research, Reliant Medical Group, Worcester, MA, ³Reliant Medical Group, Worcester, MA
Background/Purpose: There has been an increase in the prevalence of gout over the past two decades, with increasing number of patients presenting at younger age.…
Abstract Number: 2218 • 2018 ACR/ARHP Annual Meeting
Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis
Jean Liew and Gregory Gardner, Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Medically complex individuals may have contraindications to standard therapies for acute arthritis secondary to gout or calcium pyrophosphate disease (CPPD). Observational studies have demonstrated…
Abstract Number: 2219 • 2018 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Masuharu Hirano¹, Shiro Kobayashi², Eri Miyayama², Takashi Ohta¹, Masao Yamamoto² and Tomio Yamakawa³, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Development Planning Department, Nippon Chemiphar Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: Gout flare due to rapid urate reduction after initiating urate-lowering therapy (ULT) is one of the major issues in the therapy. International guidelines recommend…
Abstract Number: 2220 • 2018 ACR/ARHP Annual Meeting
Gout, Flares and Allopurinol Use: A Population Based Study
Charlotte Proudman¹, Susan Lester^2,3, David Gonzalez-Chica⁴, Tiffany Gill³, Nicola Dalbeth⁵ and Catherine Hill^6,7, ¹Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ²Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, ³Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ⁴Discipline of General Practice, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ⁵Department of Medicine, Faculty of Medical and Health Sciences., University of Auckland, Auckland, New Zealand, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷Medicine, The University of Adelaide, Adelaide, Australia
Background/Purpose: Gout flares may often be self-managed, but there is a paucity of population-based data. The aim of this study was to determine the prevalence…
Abstract Number: 2221 • 2018 ACR/ARHP Annual Meeting
Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor
Faseeh Zaidi¹, Amanda Phipps-Green², Anne-Kathrin Tausche³, Alexander So⁴, Philip Riches⁵, Mariano Andres⁶, Fernando Perez-Ruiz⁷, Michael Doherty⁸, Matthijs Janssen⁹, Leo .A.B. Joosten¹⁰, Tim Jansen¹¹, Fina Kurreeman¹², Rosa Torres¹³, Geraldine M. McCarthy¹⁴, Jeffrey Miner¹⁵, Lisa K. Stamp¹⁶, Tony R. Merriman² and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ⁴University of Lausanne, Lausanne, Switzerland, ⁵University of Edinburgh, Edinburgh, United Kingdom, ⁶Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ⁷BioCruces Health Research Institute, Barakaldo, Spain, ⁸The University of Nottingham, Nottingham, United Kingdom, ⁹Rheumatology Dept, Rijnstate Hospital, Arnhem, Netherlands, ¹⁰Radboud University Medical Center, Nijmegen, Netherlands, ¹¹VieCuri Medical Center, Venlo, Netherlands, ¹²Leiden University Medical Centre, Leiden, Netherlands, ¹³La Paz University Hospital, Madrid, Spain, ¹⁴Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁵Formerly Ardea Biosciences, San Diego, CA, ¹⁶University of Otago, Christchurch, New Zealand
Background/Purpose: Although increasing age is an important risk factor for development of gout, disease can develop in younger people. The aim of this study was…
Abstract Number: 2222 • 2018 ACR/ARHP Annual Meeting
Construct Validity of Provisional Remission Criteria for Gout: A Dual Energy CT Study
Nicola Dalbeth¹, Christopher Frampton², Maple Fung³, Scott Baumgartner³, Savvas Nicolaou⁴ and Hyon K. Choi⁵, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, New Zealand, ³Formerly Ardea Biosciences, San Diego, CA, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Provisional domains and definitions for gout remission criteria have been proposed using consensus methodology (de Lautour et al, Arthritis Care Res 2016). These criteria…
Abstract Number: 2223 • 2018 ACR/ARHP Annual Meeting
Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition (CPPD) in a Population-Based Study
Tuhina Neogi¹, Christine Peloquin¹, Yuqing Zhang^1,2, Hyon K. Choi³, Robert Terkeltaub⁴ and David T. Felson¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁴VA San Diego Healthcare System, San Diego, CA
Background/Purpose: There are no therapies available that specifically target CPPD, with treatment limited to symptomatic management. Hypomagnesemia is a recognized risk factor for CPPD, and…
Abstract Number: 2224 • 2018 ACR/ARHP Annual Meeting
Interactions between Serum Urate-Associated Genetic Variants and Sex on Gout Risk in a European Population
Ravi K. Narang¹, Ruth Topless², Murray Cadzow³, Gregory Gamble⁴, Lisa K. Stamp⁵, Tony R. Merriman³ and Nicola Dalbeth⁶, ¹Bone and Joint Research Group, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand, ²Department of Biochemistry, University of Otago, Dunedin, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Otago, Christchurch, New Zealand, ⁶Department of Medicine, Faculty of Medical and Health Sciences., University of Auckland, Auckland, New Zealand
Background/Purpose: Sex-specific differences in the effect size of genetic variants on serum urate levels have been described, with SLC2A9 variants having a greater influence on…
Abstract Number: 2225 • 2018 ACR/ARHP Annual Meeting
Exploring the Relationship between Gout and Diffuse Idiopathic Skeletal Hyperostosis (DISH): An Epidemiologic and Genetic Study
Michael Corkill¹, Ruth Topless², Adam Worthington³, Robert Mitchell³, Kate Gregory³, Lisa K. Stamp⁴, Matthew Brown⁵, Tony R. Merriman² and Nicola Dalbeth⁶, ¹North Shore Hospital, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Waitemata District Health Board, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁶University of Auckland, Auckland, New Zealand
Background/Purpose: Gout has been reported to be a risk factor for development of diffuse idiopathic skeletal hyperostosis (DISH), a condition characterized by abnormal bone formation…
Abstract Number: 2226 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The pursuit of a link between gout/hyperuricemia and dementia has led to contradictory results. Most observational studies, including population-based studies, showed that hyperuricemia was…
Abstract Number: 2227 • 2018 ACR/ARHP Annual Meeting
What Should be the Goals of Gout Therapy? a Patient Perspective
Jasvinder A. Singh, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In the absence of any available current evidence, our primary objective was to assess the goals of gout treatment from a patient perspective and…
Abstract Number: 2228 • 2018 ACR/ARHP Annual Meeting
A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
Nicholas Lebedoff¹, Sarah Gilligan¹, Andrea Barker², Curry L. Koening³, Kelly Starman⁴, Christina Gallop⁵, Bernadette C. Siaton⁶, Kalani L. Raphael^4,7 and Michael J. Battistone⁸, ¹Internal Medicine, University of Utah, Salt Lake City, UT, ²Salt Lake City VAMC and University of Utah, North Salt Lake, UT, ³Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center, Salt Lake City, UT, ⁵Primary Care, Salt Lake City VA Medical Center, Salt Lake City, UT, ⁶University of Maryland, Baltimore, MD, ⁷Nephrology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: The safety of allopurinol in the setting of chronic kidney disease (CKD) has been a controversial issue for many years. The perceived increased risk…
Abstract Number: 2229 • 2018 ACR/ARHP Annual Meeting
Can We Predict Inadequate Response to Allopurinol Dose Escalation? Analysis of a Randomized Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: The two most common causes of inadequate serum urate (SU) lowering with allopurinol are low adherence and under-dosing. Those who are adherent, but do…
Abstract Number: 2230 • 2018 ACR/ARHP Annual Meeting
Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
Estella Yeo¹, Suetonia Palmer², Peter T. Chapman³, Christopher Frampton⁴ and Lisa K. Stamp⁴, ¹Canterbury District Health Board, Christchurch, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³Christchurch Hospital, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: To explore the number of patients on haemodialysis (HD) or peritoneal dialysis (PD) with gout in Canterbury and to determine how many were receiving…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].